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ABSTRACT
Gastrointestinal symptoms (GIS) are often among the earliest presenting 
events in Fabry disease (FD), an X-linked lysosomal disorder caused by the 
deficiency of α-galactosidase A. Despite recent advances in clinical and molecular 
characterization of FD, the pathophysiology of the GIS is still poorly understood. 
To shed light either on differential clinical presentation or on intervariability of GIS 
in FD, we genotyped 1936 genetic markers across 231 genes that encode for drug-
metabolizing enzymes and drug transport proteins in 49 FD patients, using the DMET 
Plus platform. All nine single nucleotide polymorphisms (SNPs) mapped within four 
genes showed statistically significant differences in genotype frequencies between 
FD patients who experienced GIS and patients without GIS: ABCB11 (odd ratio  
(OR) = 18.07, P = 0,0019; OR = 8.21, P = 0,0083; OR=8.21, P = 0,0083; OR = 8.21,  
P = 0,0083),SLCO1B1 (OR = 9.23, P = 0,0065; OR = 5.08, P = 0,0289; OR = 8.21,  
P = 0,0083), NR1I3 (OR = 5.40, P = 0,0191) and ABCC5 (OR = 14.44, P = 0,0060). This 
is the first study that investigates the relationships between genetic heterogeneity in 
drug absorption, distribution, metabolism and excretion (ADME) related genes and 
GIS in FD. Our findings provide a novel genetic variant framework which warrants 
further investigation for precision medicine in FD.
INTRODUCTION
Fabry disease (FD [MIM:301500]), or Anderson-
Fabry disease, is a rare X-linked lipid storage disorder 
caused by mutations in the GLA gene (MIM: 300644), 
encoding the lysosomal enzyme α-galactosidase A 
(α-Gal A). Deficient activity of α-Gal A leads to a 
progressive accumulation of neutral glycosphingolipids, 
predominantly globotriaosylceramide (Gb3), in the 
vascular endothelium of skin, kidney, nervous system, 
heart and other tissue with consequent multiorgan 
dysfunction [1]. In affected males, the clinical 
presentation of FD varies from a classical phenotype 
(null or minimal α-Gal A activity), including childhood-
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onset angiokeratoma, acroparesthesias, gastrointestinal 
disorders, hypohidrosisand characteristic corneal 
and lenticular opacities [2, 3] to adult-onset variants 
(residual α-GalA activity) with only cardiac [4] or renal 
[5] symptoms. Heterozygous females show a variable 
phenotype due to random X-inactivation [6]. However, 
published data showed a high degree of intra-familial 
phenotypic variability in patients carrying the same 
mutation [7]. Enzyme replacement therapy (ERT), with 
agalsidase alfa and agalsidase beta, has been reported to be 
well tolerated and effective in FD [8–11]. Gastrointestinal 
symptoms (GIS) are reported in approximately 60% 
of FD patients and have a profound negative effect on 
their quality of life. Post-prandial abdominal pain and 
diarrhea are the most prevalent manifestations, while less 
common GIS include nausea, vomiting, and early satiety 
[12]. Despite recent advances in clinical and molecular 
characterization of FD, the pathophysiology of the GIS is 
still poorly understood.
Here, we have evaluated the intervariability of 
GIS recurrence in a cohort of 49 FD patients. In order to 
determine the involvement of genetic factors unrelated to 
α-Gal A deficiency in the pathogenesis of GIS, we have 
performed a profiling of 1936 common and complex 
functional variants (SNPs, insertions, duplications, deletions) 
across 231 genes that encode for drug-metabolizing enzymes 
and drug transport proteins using the DMET Plus platform 
(Affymetrix, Inc., Santa Clara, CA, US).
RESULTS
Prevalence of gastrointestinal symptoms
The overall prevalence of GIS in the 49 evaluated 
patients was 24.5% (n = 12). Abdominal pain was present 
in 12 patients (24.5%) while diarrhea was reported in 
11 patients (22.4%). One male patient complained only 
abdominal pain, all the other patients had more than one 
GI symptom: ten patients complained abdominal pain and 
diarrhea, one patient had heartburn, belching and bloating 
in addition to abdominal pain and diarrhea. The onset of 
GIS in our patients occurred at a median age of 9.1 years 
(range: 4–15 years). Ten out of the 12 patients with GIS 
were under ERT. After a period between 12 and 24 months 
of ERT, 40% patients (n = 4) reported an improvement in 
frequency and severity of GIS, while the remaining 60% 
(n = 6) reported no changes in GI manifestations after 
starting the treatment. Genotype-phenotype correlation 
revealed variability in the occurrence of GIS in related 
individuals carrying the same mutation.
Correlation between genetic polymorphisms and 
gastrointestinal symptoms
All 49 patients passed QC metrics and produced 
useable genotypes. The average call rate was more 
than 95%. One SNP (rs2235033/ABCB1) failed to meet 
Hardy–Weinberg equilibrium (p < 0.05) and was excluded 
from further analysis. Of the remaining 1935 SNPs, 1025 
SNPs were polymorphic in our population and were 
used in the association study. Nine SNPs in four genes 
unrelated to α-Gal A deficiency (NR1I3, ABCC5, ABCB11, 
SLCO1B1) resulted associated with GIS (Table 1).
The heterozygous genotype AG (rs2501870) in 
the NR1I3 gene and the heterozygous genotype CT 
(rs7636910) in the ABCC5 gene resulted more frequent in 
patients with GIS compared to patients without GIS (67% 
versus 27% P = 0.0191, and 92% versus 43% P = 0.0060, 
respectively) (Table 2). Four ABCB11 polymorphisms 
(rs497692, rs495714, rs496550, rs473351), in linkage 
disequilibrium (LD), significantly correlated with GIS, and 
the frequencies of the heterozygous genotypes CT were 
significantly higher in FD patients with GIS (CT = 84% 
versus 38% P = 0.0083, 92% versus 38% P = 0.0019, 84% 
versus 38% P = 0.0083 and 82% versus 38% P = 0.0083, 
respectively). In three SLCO1B1 variants (rs2291075, 
rs11045819, rs2306283) the heterozygous genotypes (CT, 
AC and AG, respectively) showed statistically differences 
between the two groups, with higher frequencies in the 
FD patients with GIS (respectively 84% versus 35% 
P = 0.0065, 58% versus 22% P = 0.0289 and 84% versus 
38% P = 0.0083, respectively), while the homozygous 
genotypes CC in rs2291075 and rs11045819 were 
associated with absence of GIS (respectively 43% 
versus 8% P = 0.0371 and 70% versus 34% P = 0.0392, 
respectively). These data were completely confirmed 
by TaqMan SNP Genotyping assays (Figure 1). All 
genotypes generated are reliable to 100% as we previously 
demonstrated [13].
DISCUSSION
The pathophysiology of GIS in FD remains poorly 
understood although it is plausible that deposition of 
Gb3 in endothelial intestinal vasculature might cause 
enteric neuropathy. Moreover, Gb3 also accumulates in 
intestinal smooth muscle, and a direct myopathic effect, 
or combined myopathy and neuropathy, has been also 
suggested [14]. Enteropathy affecting the sympathetic 
and parasympathetic divisions of the autonomic 
nervous system is also possible, being autonomic 
nerve involvement previously reported in FD [15]. The 
peripheral neuropathy in FD manifests as neuropathic 
pain, reduced cold and warm sensation and possibly 
gastrointestinal disturbances [16].
In the present study, we investigated the 
relationships between genetic variants in ADME-related 
genes and GIS in FD, genotyping 49 FD patients with the 
DMET Plus microarray, that we have previously shown 
to be a powerful tool for the detection of genetic variants 
in ADME genes related to interindividual variability to 
drug response and/or toxicity [13, 17–20]. We identified 
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Table 1: Genes and SNPs correlating with GIS in FD patients
Gene SNP Genotype P-value
NR1I3 rs2501870 AG 0,0191
ABCC5 rs7636910 CT 0,0060
ABCB11
rs497692 CT 0,0083
rs495714 CT 0,0019
rs496550 CT 0,0083
rs473351 CT 0,0083
SLCO1B1
rs2291075 CT 0,0065
rs11045819 AC 0,0289
rs2306283 AG 0,0083
Table 2: Polymorphisms associated with GIS in FD patients
Genotype number (%)
dsSNP ID* Gene Chr Alleles Patients with GIS (N=12)
Patients without GIS  
(N = 37) P-value OR (95% C.I.)
rs2501870 NR1I3 1 A/G
GG = 4 (33.0) GG =20 (54.0)
0,0191 5.4 (1.33 to 21.95)AG = 8 (67.0) AG = 10 (27.0)
AA = 0 (0.00) AA = 7 (19.0)
rs7636910 ABCC5 3 C/T
TT = 1 (8.00) TT=11 (30.0)
0,0060 14.44 (1.69 to 123.69)CT =11 (92.0) CT = 16 (43.0)
CC = 0 (0.00) CC = 10 (27.0)
rs497692 ABCB11 2 C/T
TT =1 (8.00) TT = 13 (35.0)
0,0083 8.21 (1.57 to 43.08)CT = 10 (84.0) CT = 14 (38.0)
CC = 1 (8.00) CC = 10 (27.0)
rs495714 ABCB11 2 C/T
TT = 1 (8.00) TT = 10 (27.0)
CT = 11 (92.0) CT = 14 (38.0) 0,0019 18.07 (2.10 to 155.49)
CC = 0 (0.00) CC = 13 (35.0) 0,0215 0.073 (0.004 to 1.32)
rs496550 ABCB11 2 C/T
TT = 1 (8.00) TT = 12 (32.0)
CT =10 (84.0) CT = 14 (38.0) 0,0083 8.21 (1.57 to 43.08)
CC =1 (8.00) CC = 11 (30.0)
rs473351 ABCB11 2 C/T
TT = 1 (8.00) TT = 11 (30.0)
CT =10 (82.0) CT = 14 (38.0) 0,0083 8.21 (1.57 to 43.08)
CC = 1 (8.00) CC = 12 (32.0)
rs2291075 SLCO1B1 12 C/T
CC =1(8.00) CC =16 (43.0) 0,0371 0.12 (0.01 to 1.02)
CT = 10 (84.0) CT = 13 (35.0) 0,0065 9.23 (1.75 to 48.62)
TT= 1 (8.00) TT = 8 (22.0)
rs11045819 SLCO1B1 12 A/C
CC = 4 (34.0) CC = 26 (70.0) 0,0392 0.21 (0.05 to 0.85)
AC = 7 (58.0) AC = 8 (22.0) 0,0289 5.08 (1.26 to 20.36)
AA = 1 (8.00) AA = 3 (8.00)
rs2306283 SLCO1B1 12 A/G
AA = 1 (8.00) AA = 13 (35.0)
AG = 10 (84.0) AG = 14 (38.0) 0,0083 8.21 (1.57 to 43.08)
GG = 1 (8.00) GG = 10 (27.0)
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nine SNPs within four genes (NR1I3, ABCC5, ABCB11, 
SLCO1B1) potentially associated with GIS. 
We first found a positive correlation between the 
heterozygous genotype rs2501870 in the NR1I3 gene and 
GIS. The NR1I3 gene encodes the constitutive androstane 
receptor (CAR), which plays an essential and unique role 
in both controlling the mammalian sulfation pathways and 
facilitating bile acid (BA) detoxification and transport. The 
NR1I3 rs2501870 is located in the 5′ region of the gene. 
Despite the absence of expression and/or function analysis, 
the presence of this SNP may result in the alteration of 
mRNA secondary structure, potentially influencing the 
transcription rate of NR1I3.
We also reported the association of the ABCC5 
rs7636910 with GIS. The ABCC5 gene is a member of 
the ATP-Binding-Cassette family expressed primarily in 
the colon, liver, kidney and brain, and encodes the MRP5 
protein implicated in the transport of cyclic nucleotides, 
including cAMP and cGMP [21]. The ABCC5 rs7636910 
does not change the glutamine at position 324 and so far 
its role on protein function and expression has not been 
elucidated. In addition we showed that four variants in 
ABCB11 gene correlate with GIS. This gene encodes 
for the bile salt export pump (BSEP), responsible 
for hepatocyte-canaliculus export of conjugated and 
unconjugated BAs. Reduced function of BSEP, caused 
Figure 1: Representative DMET results and TaqMan SNP validation assay. Left column: cluster graphs from DMET Console 
software displaying the signal data of all 49 samples genotyped for rs2501870, NR1I3 (A), rs7636910, ABCC5 (B), rs497692, ABCB11 
(C) and rs2291075, SLCO1B1 (D). In rs2501870, rs497692 and rs7636910 alleles are reported in reverse orientation to genome. Right 
column: representative allelic discrimination plot (right column) generated from ViiA7 Real-Time PCR System software showing allelic 
symbols for rs2501870 (A), rs7636910 (B), rs497692 (C), rs2291075 (D) evaluation. In the plot the symbol “X” is referred to the No 
Template Control.
Oncotarget5www.impactjournals.com/oncotarget
by inherited mutations or acquired factors, may lead to 
progressive intrahepatic cholestasis and severe liver 
disease [22]. BSEP expression is regulated by nuclear 
receptors. The aryl hydrocarbon receptor (AhR) and 
the pregnance X receptor (PXR) down-regulate BSEP 
expression while CAR and the farsenoid X receptor 
(FXR) up-regulate BSEP expression [23]. It also been 
shown that increased cAMP stimulates BSEP insertion 
into canalicular membrane [24]. Noteworthy, a previous 
study showed that ABCB11 overexpression in mice results 
in BA hypersecretion [25]. The ABCB11 rs497692 results 
associated with altered transport function, promoting 
skipping of exon 24 and probably leading to dysfunction 
of the hepatobiliary bile salt export pump [26]. This SNP 
was previously associated with primary biliary cirrhosis, 
intrahepatic cholestasis of pregnancy and benign recurrent 
intrahepatic cholestasis [27–29]. The other ABCB11 
variants (rs495714, rs496550 and rs473351) are located 
in 3′ region of gene, including exon 28, but no clinical 
association has been previously reported for these SNPs.
Finally, we found three SNPs (rs2291075, 
rs2306283, rs11045819) in the SLCO1B1 gene potentially 
associated with GIS. This gene encodes the organic 
anion transporting polypeptide1B1 (OATP1B1), a Na+-
independent transporter expressed on the basolateral 
membrane of human hepatocytes that mediates the hepatic 
uptake of many endogenous compounds and xenobiotics, 
such as estrogen conjugates, BAs and statins. In vitro 
studies have shown that the rs2306283 and the rs2291075 
are associated with reduced transport activity [30], while 
the rs11045819 shows unchanged transport function 
[31]. However, the strong LD between rs2306283 and 
rs2291075 leads to hypothesize a non-independent effect 
of the two SNPs. It has been reported that OATP1B1 
expression is genotype-dependent and results higher 
in livers homozygous for rs2306283, rs11045819 and 
rs2291075. Moreover, livers that are heterozygous for 
rs11045819 have higher OATP1B1 expression than the 
wild-type, while the expression of OATP1B1 in livers 
carrying a single allele of rs2291075 and rs2306283 is not 
significantly different from the wild-type [32].
Patients with FD quite often report a previous 
diagnosis of diarrhea-predominant irritable bowel 
syndrome (IBS), a functional gastrointestinal disorder 
[33, 34]. In approximately 25% to 50% of the patients 
with IBS BAs induce diarrhea either through decreased 
ileal reabsorption or increased hepatic synthesis [35, 
36]. The enterohepatic circulation (EC) of BAs is a 
physiological process mediated by a complex membrane 
transport system in the liver and intestine, regulated 
by nuclear receptors [37], as depicted in Figure 2. BAs 
are synthesized in the liver from cholesterol and are 
transported into bile ducts in conjugated form. They 
then accumulate and are stored in the gallbladder where 
they flow into the duodenum following meal-stimulated 
gallbladder contraction. After delivery into the intestinal 
lumen, the vast majority are reabsorbed by the distal 
ileum into the portal circulation and returned to the liver. 
A disruption of EC can alter the BA pool with consequent 
deregulation of the physiological process performed 
by BAs such as digestion and absorption of nutrient in 
the gut. The cause of BA diarrhea includes a deficiency 
in fibroblast growth factor 19 (FGF-19), a hormone 
produced in enterocytes in response to high intracellular 
concentration of BAs and that inhibits hepatic BA 
synthesis through the downregulation of the rate-limiting 
enzyme cholesterol 7a-hydroxylase (CYP7A1) [38]. 
However, recent pharmacogenomics evidence suggests 
that BA transporters are highly polymorphic leading to 
variable expression and function in humans [39, 40], so 
other potential causes of BA diarrhea can include genetic 
variations that affect the proteins involved in BA EC and 
synthesis. Theoretically, an excessive BA transport through 
the hepatocyte decreases their intracellular concentration 
and thus leading to enhanced BA biosynthesis; the 
increasing BA efflux that exceeds the normal capacity for 
ileal reabsorption can produce BA diarrhea.
In this study, we postulate that polymorphisms in 
NR1I3, ABCC5, ABCB11 and SLCO1B1 are associated 
with susceptibility to develop GIS in FD through an 
hypothetic mechanism that affect EC of BAs. However, 
further well-designed studies need to better investigate 
this hypothesis including methods for the diagnosis of BA 
diarrhea.
To our knowledge, this is the first study that uses 
a pharmacogenomics approach to explore genetic factors 
potentially involved in clinical manifestations in FD. Even 
if the effects associated to the identified variants remain 
to be investigated, our study is a hypothesis-generating 
early work. Further investigations will be required to 
better understand the role of these polymorphic variants 
in the pathogenesis of FD and a validation study in an 
independent FD patient group will be planned.
MATERIALS AND METHODS
Patients
49 patients (18 males; median age 40.3 years and 
31 females; median age 39.4 years) from 18 families 
were enrolled in this study between December 2012 to 
April 2015 from the Department of Medical and Surgical 
Sciences, Pediatric Unit, Magna Graecia University 
of Catanzaro and from the Department of Nephrology, 
University Federico II of Naples. All patients were 
classically affected by FD and the diagnosis was confirmed 
by enzyme and/or molecular genetic analyses. Among the 
49 FD patients, 12 experienced GIS while 37 did not. The 
mean age at diagnosis among FD patients with GIS was 
31 years (range: 4–53), while among FD patients without 
GIS was 34,9 years (range: 2–60).
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Moreover, 37 patients were under ERT at the time of 
enrolment in the study: 4 received infusions of agalsidase 
beta every 2 weeks at a dose of 1 mg/kg, while 33 received 
infusions of agalsidase alfa 0.2 mg/kg every other week, for 
an average of 5 years and 2 months (range: 11 months −11 
years and 4 months). Baseline features of our FD patients and 
mutations are reported respectively in Table 3 and Table 4. 
Laboratory and medical evaluations were 
undertaken at baseline to exclude other possible causes 
of GI complaints. All patients underwent clinical 
evaluation, laboratory tests such as full blood cell count, 
inflammatory markers (ESR and CRP), coeliac screening 
(antitransglutaminase and antiendomysial antibodies) 
including immunoglobulin levels, liver and kidney 
biochemical profiles, stool tests for infection (stool culture, 
examination for ova and parasites and for viral infection), 
fecal calprotectin, urinalysis and culture; moreover 
all patient underwent a trial with a lactose-free diet for 
Figure 2: Enterohepatic circulation (EC) of bile acids (BAs) and proteins encoded by the four genes associated with 
GIS in FD patients. Major BA transporters in human hepatocytes and enterocytes are shown. Blue arrows indicate up-regulation, red 
bars indicate down-regulation, while black arrows indicate transport across the cell. Proteins encoded by the four genes reported in the 
current study associated with GIS are represented in orange boxes. BAs are synthesized in hepatocytes from cholesterol by CYP7A1 
which is thought to be the rate limiting step in BA synthesis. BAs active FXR to inhibit CYP7A1 gene transcription. FXR induces intestinal 
hormone FGF19 which is released in the portal circulation and in the hepatocytes activates FGFR4/Klotho-β signaling inhibiting CYP7A1 
activity. In hepatocytes BSEP excretes monovalent BAs in the bile canaliculus while divalent BAs and anionic conjugates are excreted 
via MRP2. MDR3 mediates secretion of phopholipids while organic cations are excreted via MDR1. Basolateral bile acid export system 
(MRP1, MRP3, MRP4, MRP5) excretes accumulated biliary constituents. In the terminal ilieum BAs are reabsorbed by ASBT and effluxed 
on the basolateral site via OSTα/β. BAs are taken up by the hepatocytes via NTCP and OATPs transport systems. BSEP expression is 
regulated by nuclear receptors (see text for details) and BSEP insertion into canalicular membrane is stimulated by cAMP (blue dashed 
arrow). AhR = aryl hydrocarbon receptor; ASBT = apical sodium bile salt transporter; BA = bile acid; BSEP = bile salt expert pump; CAR 
= constitutive androstane receptor; CYP7A1 = cholesterol 7a-hydroxylase; FGF19 = fibroblast growth factor 19; FGFR4 = FGF receptor 4; 
FXR = farsenoid X receptor; MRP1= multidrug resistance protein 1; MRP2 = multidrug resistance protein 2; MRP3= multidrug resistance 
protein 3; MRP4 = multidrug resistance protein 4; MRP5 = multidrug resistance protein 5; NA+ = sodium ion;  NTCP = Na+-dependent 
taurocholate cotransport peptide; OATPs = Na+-independent organic anion transport proteins; OA- = organic anions; OC- = organic cations; 
OSTα/β = organic solute transporter α/β; PC = phosphatidylcholine; PXR = pregnance X receptor. 
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2 weeks or breath hydrogen testing for sugar 
malabsorption. No other cause of GIS was found in 
our FD patients. Frequency and consistency of GIS for 
each patient under ERT were evaluated every 2 weeks 
(at the time of ERT) by interviews and questionnaires 
as previously validated from our group [41]. Peripheral 
blood samples were collected from all participants after 
appropriate informed consent. The study was approved 
by the institutional review board in accordance with 
the Recommendation of the Declaration of Helsinki for 
biomedical research involving human subjects.
DMET genotyping analysis
Genomic DNA was isolated from peripheral 
blood collected in EDTA tubes, using Perfect Pure DNA 
Blood kit (5 Prime) accordingly to the manufacturer’s 
recommendations and quantitated with Quanti-iTTM 
Table 3: Baseline details of FD patients
Total Male Female
Total patients (no.) 49 18 31
Age (y; median SD) 40.3 ± 14.4 40.3 ± 10.1 39.4 ± 16.2
Under ERT 37 17 20
With Agalsidase alfa 33 16 17
With Agalsidase beta 4 0 4
Gastrointestinal symptoms (GIS) 12 7 6
 abdominal pain 12 7 5
 diarrhea 11 7 4
 other GIS 1 1 0
Table 4: Mutations and phenotype of FD patients
Family Mutations phenotype
1 g.7192-7188delCAGCC(GGCTG) classic
2 c.515G > A classic
3 c.818T > C classic
4 c.846_874delTC classic
5 c.901C > G classic
6 c.424T > C classic
7 IVS2-76_80del5 classic
8 c.335G > A classic
9 c.1184G > C classic
10 IVS4+5G > T classic
11 c.485G > A classic
12 c.1066 C > T classic
13 c.901C > T classic
14 c.1066 C > T classic
15 c.1133C > T classic
16 c.67T >G classic
17 c.680G > C classic
18 c.1021dupG classic
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PicoGreen® dsDNA Assay kit (Invitrogen). All sample 
concentrations were normalized to 60 ng/µl and 
1 µl of each DNA samples was analyzed using 
DMET plus arrays (Affymetrix Inc., Santa Clara, 
CA, US) according to the manufacturers’ indication 
as previously described by Di Martino et al. [17]. 
Briefly, the DMET Plus assay (Affymetrix Inc., Santa 
Clara, CA, US) uses Molecular Inversion Probe (MIP) 
technology to amplify the sequence-specific targets 
for each 1936 marker. The resulting target DNA were 
then enzymatic fragmented, labeled and hybridized to 
the arrays containing allele-specific oligonucleotides. 
Finally the DMET Plus arrays were scanned with the 
GeneChip Scanner 3000 (Affymetrix Inc., Santa Clara, 
CA, US) to obtain the intensity data by CEL files. 
Genotypes were calculated by DMET Console software 
version 1.1 using the Dynamic Genotype Boundaries 
algorithm (Affymetrix Inc., Santa Clara, CA, US). 
Patients with a call rate less than 95% were excluded 
from further analysis.
TaqMan® genotyping assay
DMET results were validated using pre-
designed TaqMan® Genotyping Assays (Thermo 
Fisher Scientific) provided in custom fast 96-well 
plates, according to manufacturer’s instructions. 
For each patient, we genotyped the following SNPs: 
rs2501870, rs7636910, rs2291075 and rs497692 (assay 
ID: C_16033318_20; C_25474215_30; C_1901690_1 
and C_8813572_30, respectively). Reactions were 
performed in duplicate using an endpoint plate read on 
ViiA7 Real Time PCR System (Applied Biosystem). 
Thermal Cycling conditions included an initial step 
of denaturation at 95°C for 10 min followed by 40 
cycles at 95°C for 15 sec and 60°C for 1 min. Allelic 
discrimination was made using the SDS software 
(Applied Biosystem) that plots Rn values (fluorescence 
of the reporter dye divided by the fluorescence of a 
passive reference dye) based on the fluorescence 
signals from each well.
Statistical analysis
Genotypes for all SNPs were tested for deviation 
from Hardy-Weinberg equilibrium using a χ2 test and 
SNPs that were not in equilibrium (P < 0.05) were 
excluded. By DMET-Analyzer Tool software [42] were 
analyzed the genotype frequencies by two-tailed Fisher 
exact test in two groups: FD patients with GIS versus 
patients without GIS. Results of potential interest were 
limited to those in which the p-value was ≤ 0.05. Odds 
ratios (ORs) and corresponding 95% confidence intervals 
(CIs) were calculated for 2 × 2 table using Med Calc 
v12.3.0. No correction for multiple comparisons was 
performed.
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